JPRN-UMIN000001210已完成未知
Safety and Efficacy of Bortezomib inaddtion to Adriamycin and Intermediate-Dose Dexamethasone (iPAD) in Subjects with Relapse/Refractory Multiple Myeloma with Primary Therapies ; A PhaseI/II, Multicentre, Open-Label, Single-Arm Study - iPAd theapy for multiple myeloma
Division of Medical Oncology, Hematology and Infectious Disease, Department of Medicine, Fukuoka University0 个研究点目标入组 28 人开始时间: 2008年6月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Use of bortezomib in the previous treatment. 2.History of allergic reactions to compounds containing mannitol, bortezomib, or boron 3.Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to study protocol. 4.Active infection requiring treatment 5.Active hepatitis B or C. 6.Under treatment for a cancer other than multiple myeloma 7.Impaired kidney function requiring dialysis, liver function, cardiac function or pulmonary function. 8.Non-secretory myeloma, plasmacytoma, plasma cell leukemia, and POEMS syndrome. 9.Peripheral neuropathy> grade 2 10.Pregnant, lactation or potential
研究者
相似试验
进行中（未招募）
不适用
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsEUCTR2008-004822-17-NLniversity Medical Center
已完成
2 期
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsM. Kahler.10018849Multiple myelomaNL-OMON38293niversitair Medisch Centrum Groningen73
进行中（未招募）
1 期
EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTSMultiple myelomaEUCTR2019-002626-67-ESInstitut Català d'Oncologia360
进行中（未招募）
不适用
Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantatiomultiple myeloma patients with relapse or progression of their disease after receiving an allogeneic stem cell transplantationMedDRA version: 8.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-005007-34-NLMC20
招募中
2 期
Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantatiobone marrow cancerplasmacel dyscrasia10035227NL-OMON31757niversitair Medisch Centrum Utrecht20